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The deadly coronavirus disease 2019 is caused by the 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2). COVID-19 has spread rapidly across 
the globe with countless confirmed cases deaths. The 
severity of COVID-19 is influenced by various factors 
such as age, gender, ethnicity, and comorbid 
conditions. Although many therapeutic treatments 
have been suggested, there is no approved antiviral 
treatment specific for COVID-19. Countless challenges 
associated with this pandemic has stressed the 
medical professionals to seek therapeutic strategies, 
including the use of well-researched drugs for new 
indications. Subjects with cardiovascular issues seem 
to be at an elevated risk of unfavorable outcomes in 
the COVID-19 infection.  
 
The respiratory symptoms dominate in the clinical 
presentation of COVID-19, a few subjects may also 
have significant impairment of the cardiovascular 
system. In a published report on patients with 
COVID-19, 68% had at least one concurrent health 
issue, including hypertension, diabetes mellitus and 
other cardiovascular diseases.1 There is a need to 
analyze and understand the safety of the therapeutic 
measures used in patients with COVID-19 due to the 
possible cardiac adverse effects of these drugs, 
keeping in mind that most of the infected subjects are 
aged and have more possibility of suffering from 
cardiovascular diseases. The progress in finding new 
therapeutic indications for the currently used drugs is 
advancing at a great pace and the active use of 
azithromycin   with    antimalarial     drugs    is     being  
 
 
practiced globally. The main reason behind the use of 
this combination is rooted on the pathogenetic 
understanding of the possible mechanism of antiviral 
action of chloroquine and hydroxychloroquine. This is 
apparently based on blocking the penetration of virus 
into cells by inhibition of host cell glycosylation and 
endosomal acidification.  
 
The analysis of established literature gives rise to 
apprehension about the broad use of this drug 
combination in COVID-19 patients. Chloroquine is an 
aminoquinoline derivative, initially used as an 
antiprotozoal drug. Its mechanism of action is 
associated with inhibition of nucleic acid synthesis in 
cells, and the drug has moderate immunosuppressive 
and anti-inflammatory effect. It is used for 
rheumatoid arthritis, systemic lupus erythematosus, 
autoimmune glomerulonephritis, sarcoidosis, and 
scleroderma. It also has an antiarrhythmic effect due 
to decreased excitability of the heart muscle. It has 
many contraindications like hypersensitivity, hepatic 
failure, renal failure, bone marrow depression, cardiac 
injury, rhythm disorder, neutropenia, psoriatic 
arthritis, porphyrinuria and pregnancy. The drug 
dosing restrictions are glucose-6-phosphate 
dehydrogenase deficiency, retinopathy, epilepsy, 
myasthenia, severe gastrointestinal disorders, and 
concomitant use of hepatotoxic agents. It also 
interacts with many drugs including cimetidine, 
penicillamine, phenylbutazone, cytostatics, 
levamisole, glucocorticoids, ethanol and cardiac 
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manifestations of this drug are considered to be non-
serious adverse events, and retinal, neuromuscular, 
and cardiac toxicity are classified as serious adverse 
events.2 Cardiac toxicity of the drug is well known and 
widely described in the literature, more commonly 
reported as cases of cardiomyopathy, cardiac rhythm 
disturbances and conduction impairment.3-5 Another 
antimalarial drug is hydroxychloroquine, which also 
has anti-inflammatory and immunosuppressive 
effects in systemic lupus erythematosus and 
rheumatoid arthritis, which are registered as its 
official indications.  
 
Hydroxychloroquine has cumulative activity, but side 
effects may occur relatively early. Cardiovascular side 
effects of chloroquine or hydroxychloroquine like 
cardiomyopathy, can lead to heart failure, may be fatal 
in some cases. Conduction disorders are the main side 
effect reported in patients who receive these drugs. 
Clinicians should be cautioned that cardiovascular 
side effects, even conduction abnormalities without 
severe consequences, associated with the use of 
chloroquine or hydroxychloroquine, may be initial 
toxicity manifestations and potentially irreversible.6-8 
Older patients undergo age-related physiological 
changes that are manifested in the changes of drug 
pharmacodynamics, potentially causing increased 
drug interactions and risk of side effects. Drug 
interactions and side effects associated with the use of 
antimalarial drugs in elderly may occur more 
frequently due to QT prolongation, decreased renal 
elimination, and decreased hepatic metabolism [9]. 
Hydroxychloroquine prolongs the QT interval and 
should not be prescribed in combination with other 
drugs that have the potential for cardiac arrhythmias. 
There is an increased risk of ventricular arrhythmias 
when hydroxychloroquine is used concomitantly with 
other arrhythmic agents. 
 
The choice of antibacterial agent in favor of 
azithromycin in the COVID-19 treatment regimens in 
combination with chloroquine or hydroxychloroquine 
rises concerns about two aspects: increased risk of 
cardiac arrhythmic side effects and more frequently 
reported resistance to monotherapy with this drug, 
which may affect the pneumonia treatment 
effectiveness in a patient with COVID-19. In addition, 
the decrease in treatment effectiveness may be 
exacerbated by additional immunosuppression and 
depressed intrinsic immunity associated with the 
administration of antimalarial drugs such as 
chloroquine or hydroxychloroquine. Many studies 
suggest that macrolide therapy was associated with 
the risk of cardiac complications.10-13 Mefloquine is 
another antimalarial drug developed in the USA in the 
early 1970s.14 It has no cardiac side effects but has 
psychoneurological side effects.15  
 
A systematic literature review to identify a critical 
assessment of further use of mefloquine in connection 
with the risk of psychiatric disorders and suicide risk 
did not reveal any critical comments supporting these 
risks in clinical practice for prophylactic use of 
mefloquine.16 Another study conducted on 
mefloquine, along with cepharanthine and selamectin 
as a treatment for COVID-19 demonstrated that these 
drugs showed complete inhibition of cytopathic 
effects in cell culture.17 Given the described drug 
interactions and possible side effects, clinicians 
should be vigilant in selecting optimal therapy on a 
case-by-case basis considering the presence of certain 
diseases and characteristics of particular patient. It 
should be remembered that patients with high viral 
load may develop myocarditis18 as a consequence of 
direct viral toxicity to the myocardium and myocardial 
damage, as evidenced by studies of troponin level 
changes and prognosis in this population.19 In this 
case, it should be noted that the prescription of drugs 
with cardiotoxicity should be limited. To reduce the 
risk of cardiotoxicity-related side effects, prior to drug 
prescription, a patient should be evaluated for the 
following conditions that contraindicate 
hydroxychloroquine like severe cardiac abnormalities, 
including significant rhythm and conduction 
abnormalities, chronic heart failure, cardiomyopathy, 
marked left ventricular hypertrophy, planned 
amiodarone or carbamazepine administration. The 
combination of azithromycin with mefloquine, rather 
than chloroquine/hydroxychloroquine, appears to be 
more grounded in terms of safety.  
 
However, patients with previously reported 
ventricular tachycardia and/or significant QT 
prolongation should probably refrain from 
azithromycin. To control cardiotoxicity and safety of 
the conducted therapy, instrumental and clinical 
monitoring, including ECG monitoring is required 
prior to treatment and over time, in patients at high 
risk, and in patients with a history of cardiovascular 
diseases regardless of their age. The discussed 
antiviral drug therapy could be considered as a 
pathogenetically justified approach in the treatment 
of the novel coronaviral infection, but an effective 
antiviral drug with a clearly proven effect on COVID-
19 has not yet been determined.20 Antiviral drugs, 
remdesivir and favipiravir, currently being actively 
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studied in clinical trials in patients with COVID-19, are 
candidates for the potential use in clinical practice. In 
addition, intravenous immunoglobulin and donor 
convalescent plasma donated through plasmapheresis 
by the patients, who have had the infection, within 2 
weeks of recovery and discharge, should be considered 
another pathogenetically justified strategy for the 
treatment of COVID-19. Despite all the struggles and 
hard work behind the research work focused on 
finding a gold standard treatment for COVID-19, there 
is no definite and specific outcome.  
 
CONCLUSION 
More in depth understanding of the mode of action of 
existing drugs against coronavirus with a focus on 
adverse events caused by them is required. Data on 
these drugs is very limited in context of COVID-19. 
Long term trials with large number of subjects need to 
be conducted to establish and document benefits of 
these drug combinations so that a significantly 
substantial evidence can be generated. 
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